RxDoctor Payments Data

Amanda Woodcock

Nurse Practitioner · Gulfport, MSNPI 1831720242

Payments from drug & device makers

$2,349in general payments, 2019–2025

Across 122 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$505
  • Abbott$329
  • Amgen$266
  • Esperion Therapeutics, Inc.$183
  • Pfizer$146
  • E.r. Squibb & Sons, L.L.C.$129
  • plus $792 from 22 others

What the payments were for

  • Food & beverage$2,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,349 in reported general payments places this provider in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$39,803
Medicare patients
44
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$111,944
EntrestoSacubitril/Valsartan87$94,676
XareltoRivaroxaban65$49,391
Repatha SureclickEvolocumab28$43,355
Ranolazine ErRanolazine101$6,789
Repatha SyringeEvolocumab11$6,074
BrilintaTicagrelor11$5,561
Midodrine Hcl59$2,480
Rosuvastatin Calcium251$1,613
Atorvastatin Calcium192$1,599
ClopidogrelClopidogrel Bisulfate194$1,266
Propafenone Hcl39$1,205
Valsartan70$1,202
Potassium Chloride80$1,115
Amiodarone Hcl81$1,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$146$111,944133 claims
NovartisEntresto$505$94,67687 claims
Johnson & JohnsonXarelto$45$49,39165 claims
AstraZenecaBrilinta$16$5,56111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →